Literature DB >> 16524370

APPepsilon, the epsilon-secretase-derived N-terminal product of the beta-amyloid precursor protein, behaves as a type I protein and undergoes alpha-, beta-, and gamma-secretase cleavages.

Solveig Lefranc-Jullien1, Claire Sunyach, Frédéric Checler.   

Abstract

beta-Amyloid peptide accumulates in the brain of patients affected by sporadic or familial forms of Alzheimer's disease. It derives from the proteolytic attacks of the beta-amyloid precursor protein (betaAPP) by beta- and gamma-secretase activities. An additional epsilon cleavage taking place a few residues C-terminal to the gamma-site has been reported, leading to the formation of an intracellular fragment referred to as APP intracellular domain C50. This epsilon cleavage received particular attention because it resembles the S3 Notch cleavage generating Notch intracellular domain. Indeed, APP intracellular domain, like its Notch counterpart, appears to mediate important physiological functions. gamma and epsilon cleavages on betaAPP appear spatio-temporally linked but pharmacologically distinct and discriminable by mutagenesis approaches. As these cleavages could be seen as either deleterious (gamma-site) or beneficial (epsilon-site), it appears of most interest to set up models aimed at studying these activities separately, particularly to design specific and bioavailable inhibitors. On the other hand, it is important to respect the topology of the substrates in order to examine physiologically relevant cleavages. Here we describe the obtention of cells overexpressing APPepsilon, the epsilon-secretase-derived N-terminal fragment of betaAPP. Interestingly, this N-terminal fragment of betaAPP was shown by biochemical and immunohistochemical approaches to behave as a genuine membrane-bound protein. APPepsilon undergoes constitutive and protein kinase C-regulated alpha-secretase cleavages. Furthermore, APPepsilon is targeted by the beta-secretase beta-site APP-cleaving enzyme and is subsequently cleaved by gamma-secretase. The resulting beta-amyloid peptide production is fully prevented by various gamma-secretase inhibitors. Altogether, our study shows that APPepsilon is a relevant betaAPP derivative to study gamma-secretase activities and to design specific inhibitors without facing any rate-limiting effect of epsilon-secretase-derived cleavage.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16524370     DOI: 10.1111/j.1471-4159.2006.03748.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  8 in total

1.  Herpes simplex virus type 1 infection in neurons leads to production and nuclear localization of APP intracellular domain (AICD): implications for Alzheimer's disease pathogenesis.

Authors:  Livia Civitelli; Maria Elena Marcocci; Ignacio Celestino; Roberto Piacentini; Enrico Garaci; Claudio Grassi; Giovanna De Chiara; Anna Teresa Palamara
Journal:  J Neurovirol       Date:  2015-04-30       Impact factor: 2.643

2.  Alzheimer presenilin-1 mutations dramatically reduce trimming of long amyloid β-peptides (Aβ) by γ-secretase to increase 42-to-40-residue Aβ.

Authors:  Marty A Fernandez; Julia A Klutkowski; Taylor Freret; Michael S Wolfe
Journal:  J Biol Chem       Date:  2014-09-19       Impact factor: 5.157

3.  The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in a {beta}-secretase-dependent pathway.

Authors:  Nikolai D Belyaev; Katherine A B Kellett; Caroline Beckett; Natalia Z Makova; Timothy J Revett; Natalia N Nalivaeva; Nigel M Hooper; Anthony J Turner
Journal:  J Biol Chem       Date:  2010-10-20       Impact factor: 5.157

4.  Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease.

Authors:  Nikolai D Belyaev; Natalia N Nalivaeva; Natalia Z Makova; Anthony J Turner
Journal:  EMBO Rep       Date:  2008-12-05       Impact factor: 8.807

5.  Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease.

Authors:  Gen He; Wenjie Luo; Peng Li; Christine Remmers; William J Netzer; Joseph Hendrick; Karima Bettayeb; Marc Flajolet; Fred Gorelick; Lawrence P Wennogle; Paul Greengard
Journal:  Nature       Date:  2010-09-02       Impact factor: 49.962

6.  Effect of sodium valproate administration on brain neprilysin expression and memory in rats.

Authors:  Natalia N Nalivaeva; Nikolai D Belyaev; David I Lewis; Alasdair R Pickles; Natalia Z Makova; Daria I Bagrova; Nadezhda M Dubrovskaya; Svetlana A Plesneva; Igor A Zhuravin; Anthony J Turner
Journal:  J Mol Neurosci       Date:  2011-09-20       Impact factor: 3.444

7.  TMP21 transmembrane domain regulates gamma-secretase cleavage.

Authors:  Raphaëlle Pardossi-Piquard; Christopher Böhm; Fusheng Chen; Soshi Kanemoto; Frédéric Checler; Gerold Schmitt-Ulms; Peter St George-Hyslop; Paul E Fraser
Journal:  J Biol Chem       Date:  2009-08-25       Impact factor: 5.157

8.  The β-secretase-derived C-terminal fragment of βAPP, C99, but not Aβ, is a key contributor to early intraneuronal lesions in triple-transgenic mouse hippocampus.

Authors:  Inger Lauritzen; Raphaëlle Pardossi-Piquard; Charlotte Bauer; Elizabeth Brigham; Jean-Daniel Abraham; Sébastien Ranaldi; Paul Fraser; Peter St-George-Hyslop; Ophelia Le Thuc; Vanessa Espin; Linda Chami; Julie Dunys; Frédéric Checler
Journal:  J Neurosci       Date:  2012-11-14       Impact factor: 6.167

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.